Abstract
Adeno-associated virus (AAV) was discovered about 30 yr ago as a contaminant of adenovirus preparations. Since its discovery, researchers have described many unique characteristics of AAV biology that have made it attractive as a potential vector for gene therapy. For example, AAV is not pathogenic, approx 80% of adults in the United States are seropositive, but in no case has the virus been implicated as the etiological agent for a human disease. AAV is a defective parvovirus with a single-stranded DNA genome of 4.6 kb comprising two open reading frames coding for nonstructural (Rep) and structural (Cap) proteins. The entire genome is flanked by two identical 145-basepair (bp) inverted terminal repeats (ITR), as shown in Fig. 1. Possibly, the most striking property of the virus is its inability to productively infect healthy cells in the absence of a coinfection by a helper virus (either adenovirus or herpesvirus). Thus, AAV vectors are inherently replication defective. Infection in the absence of helper virus leads to integration of the AAV genome at a specific site on the q arm of chromosome 19 to establish latent infection (1-3). This is the only known example of site-specific integration by a mammalian virus and suggests the possibility of a
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kotin, R. M., Siniscalco, M., Samulski, R. J., et al. (1990) Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87, 2211ā2215.
Kotin, R. M., Linden, R. M., and Berns, K. I. (1992) Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO.J. 11, 5071ā5078.
Samulski, R. J., Zhu, X., Xiao, X., et al. (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO. J. 10, 3941ā3950.
Podsakoff, G., Wong, K. K., and Chatterjee, S. (1994) Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol. 68, 5656ā5666.
Xiao, X. and Samulski, R. J. (1996) Long-term and efficient in vivo gene transfer into muscle tissue of immunocompetent mice with rAAV vector. J. Virol. 70, 8098ā8108.
Okada, H., Miyamura, K., Itoh, T., et al. (1996) Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther. 3, 957ā964.
Conrad, C. K., Allen, S. S., Afione, S. A., et al. (1996) Safety of single-dose administration of an adeno-associated virus (AAV)-cftr vector in the primate lung. Gene Ther. 3, 658ā668.
Afione, S. A., Conrad, C. K., Kearns, W. G., et al. (1996) In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 70, 3235ā3241.
Grant, C. A., Ponnazhagan, S., Shan-Wang, X., et al. (1997) Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. Curr. Eye. Res. 16, 949ā956.
Bennett, J., Duan, D., Engelhardt, J. F., and Maguire, A. (1997) Real-time noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest. Ophthalmol. Vis. Sci. 38, 2857ā2863.
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., and LaVail, M. M. (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 6916ā6921.
Rolling, F., Shen, W., Tabarias, H., et al. (1999) Evaluation of AAV mediated gene transfer into the rat retina by clinical fluorescent photography. Hum. Gene Ther. 10, 641ā648.
Samulski, R. J., Chang, L. S., and Shenk, T. (1989) Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63, 3822ā3828.
Snyder, R. O., Xiao, X., and Samulski, R. J. (1996) Production of recombinant adeno-associated viral vectors, in Current Protocols in Human Genetics (Dracopoli, N., Haines, J., Korf, B., et al., eds.), Wiley, New York, pp. 12.1.1ā12.1.23.
Hirt, B. (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 2, 365ā369.
Ferrari, F. K., Samulski, T., Shenk, T., and Samulski, R. J. (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227ā3234.
Fisher, K. J., Jooss, K., Alston, J., et al. (1997) Recombinant adenoassociated virus for muscle directed gene therapy. Nat. Med. 3, 306ā312.
Dong, J. Y., Fan, P. D., and Frizzeli, R. A. (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101ā2112.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Rolling, F. (2001). Generation of Recombinant Adeno-Associated Virus. In: Rakoczy, P.E. (eds) Vision Research Protocols. Methods in Molecular Medicineā¢, vol 47. Humana Press. https://doi.org/10.1385/1-59259-085-3:157
Download citation
DOI: https://doi.org/10.1385/1-59259-085-3:157
Publisher Name: Humana Press
Print ISBN: 978-0-89603-837-0
Online ISBN: 978-1-59259-085-8
eBook Packages: Springer Protocols